No Data
Beijing Konruns Pharmaceutical (603590.SH): The KC1086 project has received the clinical trial acceptance notice.
On April 22, Gelonghui reported that Beijing Konruns Pharmaceutical (603590.SH) announced that it has received the clinical trial acceptance notice for the Chemical Drug Class 1 Innovative Drug KC1086 tablets, which was fully independently developed by Beijing Konruns Pharmaceutical Co., Ltd. KC1086 is a small molecule inhibitor with a novel structure that targets Lysine Acetyltransferase 6 (KAT6) and is intended for the treatment of advanced recurrent or metastatic solid tumors.
Beijing Konruns Pharmaceutical (603590.SH): The USA tariff policy has no substantial impact on the company's Business.
Gelonghui April 9th丨Beijing Konruns Pharmaceutical (603590.SH) stated on the investor interactive platform that the company's current Business focuses on the domestic market, with revenue mainly coming from domestic sales; the core product "Sulingen" has its raw materials and production based in the country, while the sold product "Mikaixin" has its raw materials and production in Europe. Currently, there is no business relationship with the USA, and the USA's tariff policy has no substantial impact on the company's Business.
Brokerage morning meeting highlights: The USA has increased tariffs on China, but the impact on these industries in the A-shares may be limited.
In today's brokerage morning meeting, GF SEC believes that the USA's tariffs on China have a limited impact on the A-share Computer Industry; China Securities Co.,Ltd. suggested being Bullish on the Innovative Drugs industry that is currently not affected by tariffs; Galaxy Securities stated that Deep Sea Technology has entered a new stage in Global Strategy, focusing on opportunities in core equipment.
The entire pharmaceutical sector has surged sharply; what happened?
On Monday, all AH Stocks in the pharmaceutical Sector surged, with innovative drugs performing the strongest. The Yinhua CSI Innovative Drugs Industry ETF collectively rose sharply, driven by three main factors: the relaxation of collective procurement, overseas license authorizations, and improvement in Earnings Reports that will reshape the Industry landscape.
GTJA: Continuous iteration of anti-tumor therapies, domestic new drugs welcome breakthroughs.
GTJA focuses on products with significant differentiation advantages and leading companies in innovative segments.
Beijing Konruns Pharmaceutical (603590.SH): The first subject has been enrolled in the Phase II clinical study of KC1036.
Beijing Konruns Pharmaceutical (603590.SH) announced that the KC1036 tablets (abbreviated as "KC1...") that the company developed independently...
